Saito I, Suzuki A, Yokozawa M, Ono K, Miyamura R, Hamaya O
Department of Urology, Tokyo Kyosai Hospital.
Hinyokika Kiyo. 1991 Jun;37(6):663-8.
We performed basic and clinical studies on the effects of a new oral antimicrobial agent, fleroxacin (FLRX), a new quinolone derivative in male gonococcal urethritis. The antibacterial activity of FLRX against clinical strains of Neisseria gonorrhoeae was roughly comparable to that of norfloxacin and ofloxacin. FLRX was administered to 58 males with gonococcal urethritis. Two different schedules of administration were adopted. One was a single-dose of 300 mg given orally (17 cases) and the other was the oral administration of 200 mg once a day for 3 to 10 days (41 cases). Clinical evaluation was made according to the criteria of the Japanese UTI Committee. The overall efficacy rate was 98% (49/50). For complications of Chlamydia trachomatis (11 cases), the efficacy rate was 90.9% (10/11). No subjective or objective adverse reaction occurred.
我们对一种新型口服抗菌剂氟罗沙星（FLRX，一种新型喹诺酮衍生物）治疗男性淋菌性尿道炎的效果进行了基础和临床研究。FLRX对淋病奈瑟菌临床菌株的抗菌活性与诺氟沙星和氧氟沙星大致相当。58例淋菌性尿道炎男性患者接受了FLRX治疗。采用了两种不同的给药方案。一种是口服300mg单剂量（17例），另一种是每天口服200mg，持续3至10天（41例）。根据日本泌尿道感染委员会的标准进行临床评估。总有效率为98%（49/50）。对于沙眼衣原体感染并发症（11例），有效率为90.9%（10/11）。未出现主观或客观不良反应。
